O

Omada Health

Virtual care provider delivering chronic-condition management

Senior Software Engineer - Solutions Engineering

Full-Time
$156k - $224.3k+ Annual cash bonus + Equity grants
Senior
Remote in USA
Remote
Software EngineeringBackend Engineering

About the job

Requirements
  • Five to eight years of experience writing readable, tested, and efficient production code.
  • Strong experience with Ruby on Rails, or exceptional backend engineering experience in another language with willingness to ramp up quickly on Rails.
  • Experience with a relational database such as PostgreSQL.
  • Experience building and consuming APIs and integrations across service boundaries.
  • Fluency with AI-assisted development, including day-to-day use of AI coding assistants and a thoughtful, quality-conscious view of their appropriate uses.
  • Experience building API-driven automation workflows, such as with Tines, n8n, or similar tools.
  • A track record of identifying inefficiencies and delivering measurable value by connecting business or operational problems to code-based solutions.
  • Solid debugging and optimization skills.
  • A strong grasp of software development lifecycle processes and frameworks.
  • Excellent verbal and written communication and collaboration skills, including working directly with non-engineering stakeholders and translating between business needs and technical realities.
  • Experience in solutions engineering, implementation, or a customer-facing technical capacity.
  • Experience mentoring engineers or leading projects.
Responsibilities
  • Shape complex, cross-system integrations, engaging early in high-complexity work such as partner or alliance integration APIs and accounting for how systems fit together and the operational implications of the design.
  • Identify recurring toil and define reusable templates, standards, and automation; involve the engineers who own relevant systems and reconcile competing constraints.
  • Investigate root causes, determine whether issues stem from architecture, monitoring gaps, or process failures, drive corrective fixes, and ensure follow-up actions prevent recurrence.
  • Provide coding guidance and support the growth of team members without formal software engineering backgrounds who write code and build automations as part of their roles.
  • Partner with commercial, product, and engineering stakeholders to scope feasible solutions and make technical trade-off decisions for delivery.
  • Clarify ambiguous problems, scope the work, and create an executable technical plan.
  • Identify risks, edge cases, security concerns, and downstream impacts during discovery, and document deep-dive knowledge in runbooks.
  • Participate in the on-call rotation, triage and address issues affecting members, ensure timely resolution, and assist internal teams with investigations.
Desired Qualifications
  • Experience with a modern front-end framework such as React or Vue.
  • Experience in healthcare or another regulated or data-sensitive domain.

About the company

Omada Health provides virtual-first, integrated care with clinically supported programs for chronic conditions. Its online programs use evidence-based medical protocols combined with behavior science, delivered with the help of health coaches and clinical specialists to help people achieve long-term health improvements. The company serves over 1,600 enterprise customers and partners with major employers, health plans, and health systems, delivering personalized interventions for diabetes prevention, weight management, diabetes, hypertension, musculoskeletal issues, and behavioral health. Its goal is to make sustained healthy behavior possible by offering accessible, scalable care that reduces healthcare costs and improves ROI for partners.

Company Size

501-1,000

Company Stage

IPO

Headquarters

South San Francisco, California

Founded

2011

Get referred to Omada Health

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 6, 2026 revenue reached $88 million, up 43%, with $5 million net income.
  • Omada raised 2026 guidance to $334 million-$340 million and $21 million-$27 million EBITDA.
  • HCSC's expanded coverage added 1.5 million lives, and first cholesterol deployment started July 2026.

What critics are saying

  • Omada depends on a few channel giants; HCSC, Optum Rx, and Lilly control access.
  • Sean Duffy's 2027 CEO handoff risks execution drift during commercialization and profitability scaling.
  • Noom, Teladoc, and Hinge Health attack Omada's employer and payer contracts by program specialization.

What makes Omada Health unique

  • Omada's August 2026 platform spans diabetes, hypertension, cholesterol, obesity, and MSK care.
  • Omada integrates human coaches, connected devices, and AI, unlike single-condition point solutions.
  • Omada's August 2026 PBM reach includes Optum Rx, Eli Lilly, and HCSC.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Remote first - Join Omada from anywhere in the US. No matter where you’re located, we budget for travel so your team can come together.
  • Flexible vacation - Invest in yourself and your loved ones with flexible time away and monthly wellness days.
  • Parental leave - We support all new parents with competitive leave policies and flexible schedules upon return.
  • Omada program - Join our best-in-class program to reach your health goals, and invite a loved one to join you too.
  • Meeting-free days - Every Wednesday afternoon, we observe company-wide focus time with nothing on the calendar.
  • Resources to thrive - Invest in inclusion with resource groups, equity training, and a cross-functional team dedicated to belonging.

Growth & Insights and Company News

6 month growth

1%

1 year growth

1%

2 year growth

1%
GlobeNewswire
Oct 20th, 2026
Omada Health to present peer-reviewed research on improving Weight Loss and Body Composition During GLP-1 treatment at World Obesity and Weight Management Congress.

Omada Health to present peer-reviewed research on improving Weight Loss and Body Composition During GLP-1 treatment at World Obesity and Weight Management Congress. The oral presentation will share results from a 12-week comparative study showing that Omada GLP-1 Care Track members, on average, lost more weight and saw greater improvements in body composition than controls. SAN FRANCISCO, Oct. 20, 2026 (GLOBE NEWSWIRE) - Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, announced it will present research at the World Obesity and Weight Management Congress (WOC 2026) in Boston showing that members of its GLP-1 Care Track lost more weight and experienced greater improvements in body composition than GLP-1 users receiving usual care. The findings were recently published in the peer-reviewed journal Diabetes, Obesity and Metabolism.[1] GLP-1 medications can produce rapid weight loss,[2] but lean mass can account for 30% or more of the weight lost.[3,4] Lean mass is critical for overall health, as losing lean mass may contribute to reductions in resting metabolic rate[5], impaired physical function and greater susceptibility to weight regain,[6] as well as an increased risk for sarcopenia,[7] frailty, and bone loss.[6,8] While exercise and resistance training are known to be effective strategies for increasing fat loss while protecting lean mass,[1] much less is known about whether virtual care programs can improve body composition outcomes for people taking GLP-1 medications. The study followed 245 adults with obesity who had started a GLP-1 for weight loss within the previous eight weeks.[1] Of those, 151 participated in Omada's GLP-1 Care Track and 94 received usual care, which could include medication alone or other, non-Omada lifestyle programs. More than a quarter (26%) of the usual care group reported using another lifestyle or wellness program during the study.[1] After 12 weeks, compared with the usual care group, Omada members on average:[1] * Lost more weight (6.0% of starting body weight vs. 3.3%) * Reduced their body fat percentage by about twice as much (−3.3% vs. −1.6%) * Saw a larger increase in muscle mass percentage (+0.6% vs. +0.2%) * Reported greater improvements in well-being, physical functioning, and confidence in their ability to lose weight * Saw depression and anxiety symptoms drop by roughly 30%, significantly more than the usual care group The GLP-1 Care Track provides clinical support between doctor visits. Members work with a care team that includes a dedicated health coach, GLP-1-specific peer support groups, digital tools for meal logging and behavior tracking, and AI-powered nutrition support.[1] The program also includes access to an exercise specialist who provides a personalized exercise plan developed by a physical therapist. Participants measured body composition at home using bioelectrical impedance scales. "GLP-1 care is about more than how much weight you lose. It's about the quality of the weight loss, as losing too much muscle can make it harder to keep the weight off long-term," said Thomas Tsang, MD, MPH, Chief Medical Officer at Omada Health. "Too many people are left to manage side effects, exercise, and nutrition on their own once GLP-1 treatment starts. This study suggests that clinical support between doctor visits can help people achieve greater weight loss and better body composition, and protect their muscle mass." This study was completed as part of the Omada Insights Lab ANSWERS (ANalyzing Success of WEight medication with Real-world evidence and Stats) Initiative, which examines and shares real-world data from Omada's behavior change weight health programs. Omada Health's Clinical Research Scientist, Lisa A. Stanton, PhD, will present "Improving GLP-1 Weight Loss Quality with a Virtual Lifestyle Companion Program" on Tuesday, October 20, 2026, at 3:20 PM ET during the Anti-Obesity Drugs & Emerging Therapies session at WOC 2026, held October 19-21. Omada Health Omada Health (Nasdaq: OMDA) is reverse engineering the way healthcare is delivered in America, putting the space between doctor visits-where health is won or lost-at the center of care. Today's healthcare system poorly serves chronic conditions that require ongoing support outside of the exam room, like obesity, diabetes, hypertension, cholesterol, and musculoskeletal conditions. Omada's virtual-first model combines human-led care teams, connected devices, and AI-enabled technology to deliver personalized care at scale, including support for GLP-1 therapy. Omada has served more than two million members since launch across 2,000+ employers, health plans, pharmacy benefit managers, and health systems. Learn more at omadahealth.com. * Stanton LA, Naqvi JB, Devaraj SM, et al. Quality Plus Quantity: Evaluation of a Virtual GLP-1 Programme With Physical Activity Support to Promote Healthy Body Composition Change During GLP-1 Weight Loss. Diabetes Obes Metab. 2026:1-12. doi:10.1111/dom.71152. * Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183 * Prado CM, Phillips SM, Gonzalez MC, Heymsfield SB. Muscle matters: the effects of medically induced weight loss on skeletal muscle. Lancet Diabetes Endocrinol. 2024;12(11):785-787. doi:10.1016/S2213-8587(24)00272-9 * Memel Z, Gold SL, Pearlman M, Muratore A, Martindale R. Impact of GLP-1 receptor agonist therapy in patients high risk for sarcopenia. Curr Nutr Rep. 2025;14(1):63. doi:10.1007/s13668-025-00649-w * Hopkins M, Gibbons C, Blundell J. Fat-free mass and resting metabolic rate are determinants of energy intake: implications for a theory of appetite control. Philos Trans R Soc Lond B Biol Sci. 2023;378(1885):20220213. doi:10.1098/rstb.2022.0213 * Prado CMM, Heymsfield SB. Lean tissue imaging: a new era for nutritional assessment and intervention. JPEN J Parenter Enteral Nutr. 2014;38(8):940-953. doi:10.1177/0148607114550189 * Scheen AJ. GLP-1-derived therapies and sarcopenia: plea for a specific focus on at risk special populations. Diabetes Metab. 2025;52(1):101708. doi:10.1016/j.diabet.2025.101708 * Jensen SBK, Sørensen V, Sandsdal RM, et al. Bone health after exercise alone, GLP-1 receptor agonist treatment, or combination treatment: a secondary analysis of a randomized clinical trial. JAMA Netw Open. 2024;7(6):e2416775. doi:10.1001/jamanetworkopen.2024.16775

Yahoo Finance
Sep 23rd, 2026
Omada Health president sells $236K in shares under pre-set trading plan

Wei-Li Shao, president of Omada Health, sold 9,418 shares for approximately $236,000 on 12 August 2026, according to an SEC filing. The transaction was executed under a Rule 10b5-1 trading plan established in March 2026. Shao retains over 307,000 shares valued at roughly $7 million following the sale. At the time of the transaction, Omada Health shares had appreciated 24% over the preceding 12 months. Omada Health provides virtual care programmes for cardiometabolic conditions including prediabetes and hypertension. The company reported trailing-twelve-month revenue of $309.8 million and net income of $4.3 million, with a market capitalisation of $1.3 billion and 946 employees.

Associated Press
Sep 10th, 2026
Omada Health targets 80% gross margin and 30% EBITDA as revenue nearly triples to $310M

Omada Health held its inaugural Investor Day in New York, unveiling updated long-term financial targets. The virtual-first healthcare provider announced expectations of at least 20% annual revenue growth, 80% non-GAAP gross margin, and 30% adjusted EBITDA margin. From fiscal 2023 through the second quarter of 2026, Omada nearly tripled its member base from approximately 0.3 million to 1.09 million and grew revenue from approximately $123 million to $310 million. During this period, gross margin expanded from 57% to 68%, whilst non-GAAP gross margin increased from 60% to 70%. The company expects continued growth through partnerships with Optum Rx and Health Care Service Corporation. Omada plans to leverage AI-enabled automation, improved coach productivity, and increased care delivery efficiency to achieve its targets. The company has served over two million members across 2,000 employers, health plans, and health systems.

Yahoo Finance
Sep 9th, 2026
Omada Health CEO Sean Duffy sells 31,457 shares worth $735,150 under trading plan

Omada Health CEO Sean Duffy sold 31,457 shares on 1 September 2026, according to an SEC filing. The transaction was valued at approximately $735,150, with shares sold at a weighted average price of $23.37. Of the total, 21,572 shares were sold on the open market, whilst 9,885 shares were used to satisfy tax withholding obligations related to vesting equity awards. The entire transaction was executed under a Rule 10b5-1 trading plan established on 13 March 2026. Following the sale, Duffy holds approximately 1.3 million shares of common stock directly and through family trusts, plus 512,994 outstanding options. The company, which provides virtual care programmes for chronic disease management, reported $309.80 million in revenue and $4.30 million in net income on a trailing twelve-month basis.

Yahoo Finance
Aug 7th, 2026
Omada Health hits $88M revenue, swings to $5M profit with 45% member growth

Omada Health reported record second-quarter revenue of $88 million, up 43% year-over-year and 13% sequentially. The digital health company achieved GAAP net income of more than $5 million, compared with a net loss of approximately $5 million in the same quarter last year. Gross margin reached 73% on a GAAP basis, up from 66% in the prior-year quarter. Adjusted EBITDA was approximately $11 million, marking a quarterly record and an $11 million improvement year-over-year. Total members grew 45% year-over-year to approximately 1.1 million, driven by broad enrollment growth across its cardiometabolic programmes. The company raised its full-year revenue guidance to $334 million to $340 million, up from previous guidance of $322 million to $330 million. Adjusted EBITDA guidance was increased to $21 million to $27 million.